Pharma Looks to Cash in on Psychedelics as Patients Seek Alternatives to Psychotropic Drugs for Depression

Eli Lilly’s multibillion-dollar acquisition of a company that makes experimental psychedelic therapies marks the largest investment yet by a drugmaker in psychedelic medicine as a treatment for depression. But pharma’s entry into the market raises questions about patents, profits and the future of psychedelic therapy. Eli Lilly’s multibillion-dollar acquisition of AtaiBeckley […]

The post Pharma Looks to Cash in on Psychedelics as Patients Seek Alternatives to Psychotropic Drugs for Depression appeared first on Activist Post.